|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Additional Reading from MarketBeat
3 Biotech Stocks That Could Benefit from the Patent CliffAuthored by Chris Markoch. Published: 4/27/2026. 
Key Points
- Biotech M&A activity is accelerating ahead of a projected $300 billion patent cliff, creating new opportunities in smaller, innovative companies.
- Gene editing leaders like CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics offer differentiated platforms that could attract acquisition interest.
- Investors willing to take on higher risk may find outsized upside in biotech stocks developing one-time curative therapies for chronic diseases.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity: in March 2026 alone, there were 10 deals valued at approximately $31.5 billion. A key driver of that activity is the upcoming patent cliff—the period when a drug loses exclusivity and faces biosimilar competition. Analysts forecast the industry could confront roughly a $300 billion patent cliff by 2030.
Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision.
Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now. Discover the real reason behind the Iran strikes before markets react
Two large-cap biopharma companies with best-selling drugs approaching that cliff are Merck & Co. (NYSE: MRK) with Keytruda and Bristol Myers Squibb (NYSE: BMY) with Eliquis. These are established names that offer investors the relative safety of strong balance sheets and dividends. That looming revenue pressure creates opportunities for investors willing to take on risk—particularly in smaller companies that could become acquisition targets. Those targets tend to be firms developing therapies that could shift care from chronic management to one-time cures. Acquirable Assets: Which Biotechs Deserve a Higher FloorIt’s common for stocks within a sector to move together, but in biotech today, the companies with the most promise are those with acquirable assets. Investors should look for three attributes:
The underlying science is differentiated enough that a large-cap company can’t quickly replicate it. The company owns its intellectual property. The drug or therapeutic addresses an indication large enough to meaningfully move revenue and earnings for an acquirer. Many small-cap biotechs don’t meet every criterion, which is one reason the sector can be difficult to navigate. Below are three companies worth watching; each sits at a different point on the risk/maturity curve. This is not a prediction that these firms will be acquired. Rather, they check the three boxes above and offer the promise of potential one-time cures for chronic or otherwise untreatable diseases. First-Mover Advantage in Gene EditingGene editing is a paradigm-shifting opportunity, and CRISPR Therapeutics (NASDAQ: CRSP) is an established pure play in the space. Unlike many peers, CRISPR already has a commercial product: CASGEVY generated over $100 million in revenue in 2025, and patient initiations have nearly tripled year-over-year. CASGEVY treats sickle cell disease (SCD) and beta-thalassemia—large but relatively niche markets. A key growth vector may come from the company’s cardiovascular work: CTX310 is a potential one‑and‑done therapy designed to rapidly reduce triglyceride and LDL levels. CTX310 recently reported positive Phase 1 data. While there is still a runway to potential approval, those early results are encouraging. Analysts are generally bullish on CRSP, though of the 19 analysts tracked by MarketBeat, two have Sell ratings. Short interest is also approximately 24% as of this writing. Because of that volatility, investors may want to scale into a position and use dips as opportunities to increase exposure. High-Risk, High-Reward In Vivo EditingIf CRISPR Therapeutics represents the most commercially mature play, Intellia Therapeutics (NASDAQ: NTLA) is the highest-stakes bet. Intellia is a pioneer of in vivo CRISPR editing, meaning its therapies perform genetic edits directly inside the body rather than ex vivo. That distinction expands the range of diseases reachable with gene editing. Intellia’s two late-stage candidates are nexiguran ziclumeran (nex-z), developed with Regeneron for transthyretin amyloidosis (ATTR), and lonvoguran ziclumeran (lonvo-z), a wholly owned program for hereditary angioedema (HAE). Both target rare, underserved diseases where a one-time functional cure would represent a major shift from chronic management. Key 2026 catalysts include a Phase 3 data readout for lonvo‑z in HAE, expected April 27, 2026, and progress on restarting and advancing its ATTR cardiomyopathy program after the FDA lifted a clinical hold. Either catalyst could move the stock materially. NTLA is not for the faint of heart, but for investors who buy the in vivo thesis, it is the purest expression of that approach. Precision Gene Editing’s Next FrontierWhere Intellia leverages CRISPR‑Cas9, Beam Therapeutics (NASDAQ: BEAM) is developing a more precise approach. Its base editing technology acts like a molecular pencil—replacing a single genetic letter rather than cutting both DNA strands. That precision could address persistent safety concerns that have held some investors back from gene editing stocks. Beam’s most advanced wholly owned program, BEAM‑302, targets alpha‑1 antitrypsin deficiency (AATD), a genetic disorder of the lungs and liver with no curative treatment today. In March 2026, Beam reported positive updated Phase 1/2 data and said it plans to advance BEAM‑302 into pivotal testing in the second half of the year. Its sickle cell program, risto-cel, could see a U.S. approval filing as early as late 2026. Beam carries more early-stage risk than CRSP and faces nearer-term funding questions given its cash runway. But its differentiated platform and proximity to pivotal data make it a company worth monitoring for investors willing to assume that risk in exchange for the upside a successful readout or acquisition could deliver. |
No comments:
Post a Comment